

Sequestration and Microvascular Congestion Are Associated With Coma in Human Cerebral Malaria

Mark J. Ponsford,¹ Isabelle M. Medana,¹ Panote Prapansilp,^{1,3,5} Tran Tinh Hien,⁶ Sue J. Lee,⁴ Arjen M. Dondorp,^{3,4} Margaret M. Esiri,² Nicholas P. J. Day,^{3,4} Nicholas J. White,^{3,4} and Gareth D. H. Turner^{3,4,5}

¹Nuffield Department of Clinical Laboratory Sciences; ²Department of Neuropathology, and ³Nuffield Department of Clinical Medicine, The John Radcliffe Hospital, University of Oxford, United Kingdom; ⁴Mahidol-Oxford Research Unit, and ⁵Department of Tropical Pathology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; and ⁶Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

The pathogenesis of coma in severe *Plasmodium falciparum* malaria remains poorly understood. Obstruction of the brain microvasculature because of sequestration of parasitized red blood cells (pRBCs) represents one mechanism that could contribute to coma in cerebral malaria. Quantitative postmortem microscopy of brain sections from Vietnamese adults dying of malaria confirmed that sequestration in the cerebral microvasculature was significantly higher in patients with cerebral malaria (CM; n = 21) than in patients with non-CM (n = 23). Sequestration of pRBCs and CM was also significantly associated with increased microvascular congestion by infected and uninfected erythrocytes. Clinicopathological correlation showed that sequestration and congestion were significantly associated with deeper levels of premortem coma and shorter time to death. Microvascular congestion and sequestration were highly correlated as microscopic findings but were independent predictors of a clinical diagnosis of CM. Increased microvascular congestion accompanies coma in CM, associated with parasite sequestration in the cerebral microvasculature.

Cerebral malaria (CM) is a common clinical presentation and cause of death in adults with severe malaria in many parts of the world. CM causes a diffuse encephalopathy associated with reduced levels of consciousness or coma, often accompanied by seizures [1]. Focal neurological deficits are relatively unusual. CM represents the lethal end of a disease spectrum, because the majority of *Plasmodium falciparum* malaria cases involve either asymptomatic parasitemia or mild clinical disease. The clinical presentation of malaria depends on both host and parasite factors, including age and immunity. In areas where malaria is highly endemic, young children

are most at risk of severe disease. Migrant workers, nonimmune travelers, or persons growing up in areas of low seasonal transmission remain vulnerable to severe malaria throughout life. CM causes 15%–20% mortality despite treatment [2] and long-term neurological sequelae or developmental/cognitive impairment in as many as 1 in 4 child survivors [3, 4]. This results in a continued major worldwide burden of mortality and morbidity, despite improved malaria control measures, such as insecticide-treated bed nets and introduction of early diagnosis and treatment with artemisinin combination therapies [5, 6]. The need to understand the pathophysiology of CM is therefore important in the search for adjuvant neuroprotective treatments for coma.

Pathological studies of brain tissue samples from patients dying of severe malaria have reported a range of findings, the most common of which is the sequestration of parasitized red blood cells (pRBCs) in cerebral microvessels in human adults [7–10] and children [11]. Erythrocytes infected with the later trophozoite and schizont stages of the parasite disappear from the peripheral circulation and preferentially localize in

Received 13 November 2010; accepted 4 April 2011; electronically published 29 December 2011.

Correspondence: Gareth D. H. Turner, MA, BM, BCh, DPhil, FRCPath, Mahidol-Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, 3rd Fl, 60th Anniversary Chalermprakiat Building 420/6, Rajvithi Rd, Bangkok, Thailand 10400 (gareth@tropmedres.ac).

The Journal of Infectious Diseases 2012;205:663–71

© The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com

DOI: 10.1093/infdis/jir812

microvessels through specific molecular adhesion between parasite-encoded molecules, such as PfEMP-1, on the pRBC surface, and host ligands, such as CD36 or ICAM-1, on vascular endothelium [12, 13]. Sequestration is a pathological hallmark of human malaria, in contrast with the predominantly inflammatory picture seen in the brain microvasculature in murine models of experimental malaria, which lack cyto-adherent pRBC sequestration [14, 15].

Sequestration occurs to a variable degree throughout the microvasculature in different vital organs, and previous quantitative light and electron microscopic studies have confirmed a quantitative association between sequestration and coma, with higher levels of sequestration seen in the cerebral microvasculature in patients dying of CM [7–11]. In the brain, sequestration causes functional and structural changes to cerebral endothelial cells [16, 17], leading to activation and changes in blood-brain barrier permeability and contributing to secondary neuropathological events, including cerebral edema and axonal injury [18].

Cytoadherence to vascular endothelial cells is one of several different adhesion phenotypes demonstrated by *P. falciparum*-infected pRBCs, which also bind in rosettes to uninfected red blood cells (uRBCs), host leukocytes, or other pRBCs in platelet-mediated clumps [19]. The formation of aggregates of cells in vitro has been linked with disease severity and may predispose to microvascular obstruction and interference with blood flow [20]. Studies have shown that the rheology of uRBCs in malaria is abnormal [21] and that ring-stage parasites, which lack cytoadherence phenotype, also preferentially sequester in the brain [9]. We were therefore interested in examining microvascular obstruction in the cerebral microvasculature to determine whether there was a relationship with sequestration or coma.

The role of vascular obstruction in causing coma and death, compared with other pathological processes, such as metabolic changes, inflammation, or edema, remains a subject of controversy. Imaging studies suggest that adult patients with CM show mildly swollen brains [22], although without frank brain stem herniation in the majority of cases. The relative contributions of extravascular edema and intravascular congestion, caused by sequestration or congestion, are unclear. We performed quantitative morphometric and immunohistochemical analysis of postmortem brain specimens from Vietnamese adults with fatal severe malaria, with and without CM, to examine the relationship between parasite sequestration, intravascular congestion, and coma.

METHODS

Clinical Definitions and Specimen Collection

Cortical brain samples were obtained from patients who died of severe *P. falciparum* malaria in a large double-blind comparative trial of parenteral artemether vs quinine for the treatment of

severe malaria conducted at the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, during 1991–1996 [23]. Autopsy was performed as quickly as possible (median time to autopsy, 7 hours); the brain was removed whole and preserved in 10% buffered formalin before a formal brain cut within 6 weeks. Samples taken from the cortex, including white and grey matter in the same block, were embedded and processed using standard histological techniques to formalin-fixed, paraffin-embedded blocks. Patients with CM (n = 21) in this study were defined clinically according to the World Health Organization criteria [1], rather than histologically. This means that patients had a Glasgow Coma Score (GCS) <11 (at admission or defined by neurological examination every 4 hours during the course of disease before death), with associated peripheral parasitemia with *P. falciparum* proven on microscopy of serial blood smears, and exclusion of other causes of unconsciousness, such as status epilepticus, hypoglycemia, or other central nervous system infections. Patients were defined as not having CM (n = 23) when the GCS was not <11 at any stage before death. Some of this group survived for days after admission and had cleared parasitemia from the peripheral blood smear (and on subsequent histological examination from the cerebral microvasculature) at the time of death but died of other complications of disease, such as renal failure or respiratory disease. None of the non-CM patients had coma at admission without peripheral parasitemia; during subsequent postmortem examination, none of the patients in this study had meningitis or other causes of death that may have simulated severe malaria premortem.

Nonmalarial control samples (n = 10) were from patients dying of non-neurological causes and were collected postmortem at the John Radcliffe Hospital, Oxford, United Kingdom, during 1995–2000. Eight control subjects were age-matched to the patients with malaria, and 2 control subjects were older patients, although there was no statistically significant difference in the mean age between the control and malaria groups (controls: median age, 37 years; interquartile range [IQR], 30–56 years). Brain samples were collected using autopsy protocols as described elsewhere [10, 24]. Use of postmortem samples from both the malaria autopsy study in Vietnam and control subjects in Oxford was with informed consent of the relatives of the deceased, and all protocols for use of the tissue samples were approved by local and institutional ethical review boards. Clinical details of the malaria and control cases are shown in Table 1.

Immunohistochemistry

Immunohistochemistry was performed on cortical brain sections (from the frontal, parietal, or occipital lobes) with use of antibodies to glycophorin A as a marker of red blood cells (RBCs; clone JC159) and CD31 (clone JC70A) as a constitutive vascular marker (both gifts from Jackie Cordell, OxFABs, NDCLS, University of Oxford). Paraffin sections were dewaxed

Table 1. Clinical Details of Patients With Malaria

Patient	Age, y	Sex	Admission Parasite Level, Parasites/ μ L	Admission GCS	WHO Diagnosis	Other Clinical Complications
1	24	M	67 824	4	CM	J
2	50	F	8290	14	NCM	Sh, J, ARF
3	30	M	529 278	3	CM	J, Sh, PEd, HyperP
4	51	F	69 206	5	CM	An, Hyp, ARF
5	26	M	3140	11	NCM	An
6	27	M	1 044 866	15	NCM	Sh, Hyp, ARF, An, PEd, HyperP
7	46	M	212 264	3	CM	An, J
8	43	M	105 504	5	CM	Sh, PEd, HyperP
9	34	M	805 912	15	NCM	ARF, AN, Ped
10	44	M	221 558	7	CM	ARF, J, PEd
11	40	F	4522	14	NCM	Hyp, ARF, An, J, PEd
12	33	M	1 450 680	15	NCM	ARF, An, J, HyperP
13	44	F	15 072	7	CM	Sh, An
14	28	M	546 360	9	CM	Sh, ARF, HyperP
15	33	M	121 330	14	NCM	Sh, ARF, An, J
16	28	M	619 208	11	NCM	ARF, An, J, HyperP
17	27	M	55 264	15	NCM	An
18	47	M	1 161 298	14	NCM	Sh, ARF, HyperP
19	28	M	45 342	8	CM	Sh, Hyp, ARF, An, J
20	34	M	150 720	8	CM	Sh, Hyp, ARF, An, J
21	22	F	802 584	12	NCM	Sh, Hyp, ARF, HyperP
22	35	M	119 320	7	CM	Sh, Hyp, ARF, J, PEd
23	24	M	1 026 152	14	NCM	Sh, J, PEd, HyperP
24	54	M	3517	11	NCM	Sh, ARF, An, J
25	56	F	21 101	13	NCM	Sh, ARF, J, PEd
26	36	M	193 424	8	CM	Sh, Hyp, ARF, J, HyperP
27	22	M	112 538	7	CM	Sh, ARF, J, PEd
28	22	M	47 728	14	NCM	Sh, ARF, An, J
29	32	M	241 152	15	NCM	Sh, ARF, An, J
30	30	M	412 847	7	CM	Sh, ARF, An, J
31	50	F	76 365	15	NCM	Sh, ARF, An, J
32	36	F	300	6	CM	Sh, Hyp, ARF, An, J
33	22	M	768 421	11	NCM	Sh, ARF, An, J, HyperP
34	25	M	480	15	NCM	Sh, Hyp, ARF, An, J
35	25	M	335 980	15	NCM	Hyp, ARF, An, J
36	43	F	567 712	15	NCM	Sh, Hyp, ARF, An, J, PEd, HyperP
37	69	M	92 442	8	CM	Sh, Hyp, ARF, An, J
38	63	M	120 576	10	CM	Sh, Hyp, An, PEd
39	22	M	297 421	7	CM	Sh, Hyp, J, PEd
40	63	M	136 653	11	NCM	Sh, ARF, An, J, PEd
41	32	M	11 304	15	NCM	Sh, ARF, J
42	45	F	89 553	10	CM	Sh, J
43	30	M	21 980	7	CM	An, J
44	52	F	7536	8	CM	Sh, Hyp, An

Control Patients	Age (y)	Sex	Neurological History	Additional Clinical History
1	30	M	None	Hemorrhagic pericarditis, splenomegaly, myelodysplasia
2	56	F	Stupor due to depression/schizophrenia	Aspiration; dehydration; bronchopneumonia
3	35	M	None	Extensive severe burns of the skin; smoke inhalation
4	35	M	Epilepsy; previous encephalitis	PEd
5	27	M	Unconscious, right-sided focal	PEd; anorexia nervosa; Hyp
6	23	F	None	Sickle cell trait; severe hemorrhage
7	45	M	None	Splenomegaly
8	39	F	None	Chronic renal failure; gastric bleed
9	95	F	None	Hepatocellular carcinoma
10	86	M	None	Acute upper GI bleeding and ischemic heart disease

Abbreviations: An, anemia; ARF, acute renal failure; CM, cerebral malaria; GCS, Glasgow Coma Score; GI, gastrointestinal; Hyp, hypoglycemia; HyperP, hyperparasitemia; J, jaundice; NCM, non-cerebral malaria; PEd, pulmonary edema; Sh, shock; WHO, World Health Organization.

and rehydrated and then underwent microwave (for glycophorin) or trypsin antigen retrieval (for CD31), according to standard protocols, as described elsewhere [25, 26]. The primary antibodies were incubated for 45 minutes on the section, the slides were washed in Tris buffered saline 3 times for 5 minutes, and incubation was done with biotinylated goat antimouse immunoglobulin for 30 minutes, followed by Streptavidin ABCComplex alkaline phosphatase. The chromogen used was the new fuchsin substrate system (all kits and substrates obtained from DAKO). The reaction was observed under a microscope and quenched by washing with Tris buffered saline. Slides were mounted in Aquamount (BDH) and counterstained with hematoxylin. Negative controls comprised sections immunostained using the aforementioned methods, except for omission of the primary antibody.

Microscopy and Quantitation of Vessels by Image Analysis

Images were captured under $\times 250$ magnification with use of QImaging software with a Zeiss microscope and analyzed using Adobe Photoshop software. CD31 and glycophorin were used as markers for endothelial cells and the erythrocyte membrane, respectively, on slides of cortical brain. The number of vessels stained with CD31 was quantitated with a graticule to provide a measure of vessels per unit area of cortex (per square millimeter). This was done in total for the section and using separate counts for grey and white matter areas. The individual counts of vessels from 6 separate fields from each case were averaged to produce a vessel density per square millimeter for each case. This single figure was correlated with clinical, biochemical, and histopathological data.

To assess microvascular congestion, the blood vessels examined were defined as small- to medium-sized vessels (2–10 erythrocytes in diameter, representing small arterioles and venules) that contained RBCs on glycophorin immunostaining (Figure 1). Congestion was defined by the presence in a vessel lumen of erythrocytes (both uninfected and infected) staining positively with glycophorin. Congestion was therefore a measure of the number of small vessels containing RBCs in a section.

Sequestration was defined morphologically as the presence of pRBCs in a vessel. Both uRBCs and pRBCs stained for glycophorin; thus, the presence of malaria pigment in RBCs or the presence of a visible parasite nucleus was used to differentiate between pRBCs and uRBCs. The number of vessels showing either congestion or sequestration was quantitated and calculated as a percentage of the total vessel count (ratio of congested or sequestered vessels to total vessels on CD31 staining).

Statistical Analysis

All analyses were performed using SPSS, version 17, or Stata, version 11 (StataCorp). Comparisons were made across the 3 groups: CM, non-CM, and controls. Differences between groups were assessed using the Fisher exact test for categorical variables and the Kruskal-Wallis test for continuous variables. Variables

were log-transformed to a normal distribution when possible, but analysis of variance was used for normally distributed continuous variables only if the variances were similar for all groups. To further elucidate the relationship between exposure and outcome, post hoc pairwise comparisons (ie, CM vs non-CM, CM vs controls, and non-CM vs controls) were made only when the initial comparison showed a significant association or when data were available for only the 2 severe malaria groups. Student *t* test or Mann–Whitney *U* test was used to assess pairwise comparisons, as appropriate. Correlations for continuous variables among patients with malaria were tested using Spearman rank correlation coefficient.

To quantify the risk associated with clinical and neuropathological features that were significant predictors of cerebral malaria, logistic regression modeling was used. Cerebral malaria was the dependent variable, and all quantitative measures of neuropathology that were significant in the univariate analysis at $P < .05$ were included as covariates. The best predictor or combination of predictors was determined using the likelihood ratio test and by checking the area under the receiver-operating characteristic (ROC) curves. Goodness-of-fit for the models was confirmed using the Homer-Lemeshow χ^2 test.

No adjustment was made for multiple comparisons; however, for P values $> .001$, exact numbers are reported so that a Bonferroni-Dunn correction can be calculated (ie, $\alpha = .05/k$, where k = number of tests).

RESULTS

Patients with CM showed a higher degree of congestion, as measured by the number of congested blood vessels per unit area of the cerebral cortex (median density, 39.7 blood vessels/mm²; IQR, 19.8–48.4 blood vessels/mm²), compared with non-CM (9.52 blood vessels/mm²; IQR, 4.76–20.6 blood vessels/mm²; $P = .002$) and nonmalarial controls (8.73 blood vessels/mm²; IQR, 7.14–15.9 blood vessels/mm²; $P = .007$) (Figure 1D). There was no statistically significant difference in congestion between controls and patients with non-CM ($P = .78$), implying that the differences in observed vascularity and microvascular congestion were not simply attributable to postmortem leaching of RBCs from patent vessels.

The difference among patients with CM and other clinical groups remained statistically significant when adjusted for variation in the vessel density between areas of the cortex. Grey matter, which normally has a higher density of vessels than white matter [27, 28], logically showed a higher degree of congested vessels (grey matter to white matter ratio: CM, 1.55 [median, 44.4; IQR, 17.5–68.3 to 28.6; IQR, 12.7–38.1], non-CM, 1 [median, 9.52; IQR, 4.76–30.2 to 9.52; IQR, 3.17–19.1], controls, 1.30 [median, 10.3; IQR, 7.94–14.3 to 7.94; IQR, 3.17–11.1]), although this was only borderline significantly different in cases of cerebral malaria ($P = .06$).




Figure 1. A–C, Images of cortical brain sections from patients with malaria that were stained for glycophorin A. A, Low-power image showing noncongested vessels. Examples of vessels without erythrocytes indicated with arrows (magnification $\times 250$; scale bar, 100 μm ; counterstained with hematoxylin). B, Low-power image showing vessels congested with parasitized and nonparasitized erythrocytes (arrows; magnification $\times 250$; scale bar 100 μm ; counterstained with hematoxylin). C, High-power image of a congested vessel showing both infected and uninfected red blood cells in a congested vessel (scale bar, 100 μm). D, Box plots showing a comparison of the number of congested vessels per square millimeter in non-cerebral malaria, cerebral malaria, and control cases. Boxes show median values with interquartile ranges and limiting values.

Sequestration of pRBCs was significantly higher in the cortical brain sections of patients with CM than in patients with non-CM ($P = .01$) (Table 2 and Figure 2A). The percentage of congested microvessels was strongly positively correlated with percentage of vessels showing sequestration of parasitized erythrocytes (Spearman $\rho = 0.85$; $P < .0001$) (Figure 2B). Moreover, both sequestration and congestion were inversely associated with time to death after admission to hospital (Spearman $\rho = -0.61$ and $\rho = -0.51$, respectively; both $P < .001$). The level of consciousness, as measured by the GCS, was also inversely correlated with both parameters (Spearman $\rho = -0.48$; $P = .001$ for sequestration; Spearman $\rho = -0.52$; $P = .0003$ for congestion).

The clinical and neuropathological correlates of CM and non-CM were examined (Table 2). There was no difference between

the CM and non-CM groups in terms of their age, admission parasitemia, or type of treatment received after admission (either artemether or quinine). Across the malaria groups, drug type was also not associated with a difference in the degree of congestion or sequestration observed microscopically ($P = .19$ and $P = 0.61$, respectively). No relationship was found between the degree of sequestration or congestion and hematocrit ($P = .08$ and $P = 0.34$, respectively), implying that lower rates of congestion or sequestration cannot be explained simply by the presence of anemia.

A number of clinical features were not associated with CM in this series, including shock, anemia, jaundice, hypoglycemia, pulmonary edema, and the incidence of convulsions before admission. Brain weight at autopsy and cerebrospinal fluid

Table 2. Statistical Comparison of the Clinical Parameters of Cerebral Malaria and Non-Cerebral Malaria Cases

	CM	Non-CM	P Value
Number of patients	21	23	
Age (years)	36 (22–69)	32 (22–63)	.31
Drug therapy	A = 11, Q = 10	A = 7, Q = 16	.22
Maximum temperature, °C	39.5 (38.3–40)	39.0 (38.3–39.8)	.79
Maximum heart rate, beats/min	120 (120–140)	120 (116–140)	.95
Time to death, h	36.0 (13–56)	44 (18–123.5)	.31
At admission			
Glasgow Coma Score	7 (3–10)	14 (11–15)	.0001
Hematocrit, %	30 (8–50)	28 (6–47)	.66
Geometric mean (95% CI) parasitemia/μL	80 665 (37 403–173 963)	96 144 (34 836–265 346)	.78
Lactate (plasma), mmol/L	6.7 (2.2–18.3)	3.7 (0.4–1.03)	.03
Creatinine (serum), mg/dL	2.3 (0.7–7.5)	4.4 (1.03–11)	.02
White cell count × 10 ⁻⁸ , cells/mm ³	12.8 (3.0–31.5)	11.0 (2.0–36.8)	.30
Platelet count × 10 ⁻⁴ , cells/mm ³	32 (20–194)	40 (12–120)	.66
Bilirubin, mg/dL	5.2 (1.0–18.8)	9.9 (0.6–18.0)	.21
CSF opening pressure, /mm H ₂ O	17 (10.5–22); n = 16	14 (13.5–19); n = 5	.90
CSF protein	140 (70–208); n = 18	70 (53–130); n = 6	.04
CSF white cell count	3 (0–6); n = 17	0 (0–2); n = 6	.04
No. (%) with acute renal failure	9 (42.9)	17 (73.9)	.07
No. (%) with jaundice	14 (66.7)	18 (78.3)	.50
No. (%) with shock	8 (34.8)	6 (28.6)	.75
No. (%) with hypoglycemia	2 (9.52)	4 (17.4)	.67
No. (%) with pulmonary edema	1 (4.76)	2 (8.70)	1.0
No. (%) with convulsions	5 (25.0)	1 (4.35)	.08
No. (%) with dialysis	3 (47.8)	11 (14.3)	.02
Histopathological			
Sequestration, %	84.9 (68.8–93.2)	13.7 (0–73.2)	.01
Congestion, vessels/mm ³	39.7 (19.8–48.1)	9.52 (4.76–20.6)	.002
Brain mass, g	1335 (1240–1400)	1300 (1290–1400)	.95

All values are median (interquartile range), unless otherwise specified. Results in bold show significant differences between CM and Non-CM patient groups, $P < .05$. Abbreviations: A, Artemether; CI, confidence interval; CM, cerebral malaria; CSF, cerebrospinal fluid; Q, Quinine.

(CSF) opening pressure were also not significantly different between the 2 groups.

However, microvascular congestion, sequestration of pRBCs, admission lactate, CSF protein level, and CSF white blood cell count were significantly associated with cerebral malaria with use of the Mann–Whitney U test (Table 2). When the risk was quantified using logistic regression, CSF protein level ($n = 24$; odds ratio [OR], 1.03; 95% confidence interval [CI], .99–1.06) and CSF white blood cell count ($n = 23$; OR, 1.75; 95% CI, .81–3.79) were no longer significantly associated with CM possibly because of small sample size. Coma score was significantly associated because of the clinical definition of the CM group; risk could not be quantified, because all patients with GCS ≥ 11 were defined as having non-CM and all patients with GCS < 11 were considered to have CM.

Acute renal failure, as defined by higher levels of plasma creatinine, were associated with lower risk of CM (OR, 0.71;

95% CI, .52–.97), as was the requirement for treatment by dialysis after admission (OR, 0.18; 95% CI, .04–.79). Higher levels of admission lactate level were borderline significantly associated with higher odds of CM (OR, 1.16; 95% CI, .99–1.36). When assessed using likelihood ratio testing, percentage vessel sequestration was a good independent predictor (OR, 1.02; 95% CI, 1.01–10.4; ROC area, 0.72), but microvascular congestion was the best independent predictor of CM (OR, 1.07; 95% CI, 1.02–1.12; $P = .0001$; ROC area, 0.77). Multivariate combinations of the aforementioned variables either did not provide a good model fit or did not predict as well as the single covariate models.

DISCUSSION

Sequestration of *P falciparum*–parasitized erythrocytes in the cerebral microvasculature has been a consistent feature of pathological studies of CM since the seminal studies of Marchiafava

and cytoadherent infected erythrocytes is different from other causes of large vessel hypoxic and/or ischemic damage. Whether coma is a neuroprotective response is an important question, because efforts to reverse it with adjuvant therapies could then risk exacerbating injury, causing reflow damage or contributing to long-term neurological sequelae.

Recent work in the *Plasmodium coatneyi* primate model of CM (in which there is significant cerebral sequestration) using positron-emission tomography to map glucose use revealed diffuse and heterogeneous reduction of metabolism in the cortex during the acute phase of infection [36], which is consistent with an impaired microcirculation. A functioning microcirculation protects organs from the effects of diminished oxygen and metabolite supply, and impairment of microcirculatory function may cause diminished oxygenation despite normal overall oxygen delivery to an organ [37]. Changes in microcirculatory function has been directly visualized in the buccal and rectal vessels in patients with severe malaria, in which the patterns of obstruction and flow differ from sepsis, a widely used model of the contribution of microcirculatory dysfunction to tissue injury [38]. Our results imply that dysregulation of the control of microcirculatory blood supply occurs in the brain during CM.

Brain swelling in CM is a variable finding in radiological and postmortem studies of adults with fatal malaria [21]. With greater occlusion of cerebral blood flow, increased hydrostatic pressure might lead to hemorrhages and cerebral edema. However, preliminary examination of the incidence of edema, fibrinogen leakage, and microscopic hemorrhages in these patients reveal no association with the degree of sequestration or congestion [35]. Systemic, as opposed to local, microcirculatory factors may also contribute to defects in cerebral blood flow during severe malarial illness. Shock is present in only 12% of cases in both adult [39] and pediatric [40] severe malaria but was seen in a disproportionately high number of the fatal cases in this study, reflecting the multisystemic nature of fatal disease in this group. The high incidence of acute renal failure in adults may be important, as shown here by the inverse relationship between creatinine levels and congestion, but requires further investigation.

Our findings emphasize the importance of cerebral microvascular obstruction in contributing to coma during severe malarial in humans. They confirm the association between sequestration of malaria-infected erythrocytes and show, for the first time to our knowledge, a strong association between coma, sequestration, and inappropriate microvascular congestion in human CM.

Notes

Financial support. This work was supported by the Wellcome Trust of Great Britain; the NIHR Biomedical Research Centre Programme, Oxford; The John Fell Fund of Oxford University; and the Thrasher Research Fund, USA (grant number 02827-2).

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. *Trans R Soc Trop Med Hyg* **2000**; 94(Suppl 1):S1–90.
2. Newton CR, Taylor TE, Whitten RO. Pathophysiology of fatal falciparum malaria in African children. *Am J Trop Med Hyg* **1998**; 58: 673–83.
3. Carter JA, Mung'ala-Odera V, Neville BG, et al. Persistent neurocognitive impairments associated with severe falciparum malaria in Kenyan children. *J Neurol Neurosurg Psychiatry* **2005**; 76:476–81.
4. John CC, Bangirana P, Byarugaba J, et al. Cerebral malaria in children is associated with long-term cognitive impairment. *Pediatrics* **2008**; 122:e92–9.
5. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. *Cochrane Database Syst Rev* **2004**; (2):CD000363.
6. White NJ. The role of anti-malarial drugs in eliminating malaria. *Malar J* **2008**; 7(Suppl 1):S8.
7. MacPherson GG, Warrell MJ, White NJ, Looareesuwan S, Warrell DA. Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. *Am J Pathol* **1985**; 119:385–401.
8. Pongponratn E, Riganti M, Punpoowong B, Aikawa M. Microvascular sequestration of parasitized erythrocytes in human falciparum malaria: a pathological study. *Am J Trop Med Hyg* **1991**; 44:168–75.
9. Silamut K, Phu NH, Whitty C, et al. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. *Am J Pathol* **1999**; 155:395–403.
10. Pongponratn E, Turner GD, Day NP, et al. An ultrastructural study of the brain in fatal *Plasmodium falciparum* malaria. *Am J Trop Med Hyg* **2003**; 69:345–59.
11. Taylor TE, Fu WJ, Carr RA, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. *Nat Med* **2004**; 10: 143–5.
12. Kraemer SM, Smith JD. A family affair: var genes, PfEMP1 binding, and malaria disease. *Curr Opin Microbiol* **2006**; 9:374–80.
13. Chakravorty SJ, Craig A. The role of ICAM-1 in *Plasmodium falciparum* cytoadherence. *Eur J Cell Biol* **2005**; 84:15–27.
14. White NJ, Turner GD, Medana IM, Dondorp AM, Day NP. The murine cerebral malaria phenomenon. *Trends Parasitol* **2010**; 26:11–15.
15. de Souza JB, Hafalla JC, Riley EM, Couper KN. Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. *Parasitology* **2010**; 137:755–72.
16. Tripathi AK, Sha W, Shulaev V, Stins MF, Sullivan DJ. *Plasmodium falciparum*-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endothelium. *Blood* **2009**; 114:4243–52.
17. Jambou R, Combes V, Jambou MJ, et al. *Plasmodium falciparum* adhesion on human brain microvascular endothelial cells involves transmigration-like cup formation and induces opening of intercellular junctions. *PLoS Pathog* **2010**; 6:e1001021.
18. Medana IM, Turner GD. Human cerebral malaria and the blood-brain barrier. *Int J Parasitol* **2006**; 36:555–68.
19. Rowe JA, Claessens A, Corrigan RA, Arman M. Adhesion of *Plasmodium falciparum*-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications. *Expert Rev Mol Med* **2009**; 11:e16.
20. Rogerson SJ, Grau GE, Hunt NH. The microcirculation in severe malaria. *Microcirculation* **2004**; 11:559–76.
21. Dondorp AM, Pongponratn E, White NJ. Reduced microcirculatory flow in severe falciparum malaria: pathophysiology and electron-microscopic pathology. *Acta Trop* **2004**; 89:309–17.
22. Looareesuwan S, Wilairatana P, Krishna S, et al. Magnetic resonance imaging of the brain in patients with cerebral malaria. *Clin Infect Dis* **1995**; 21:300–9.

23. Tran TH, Day NP, Nguyen HP, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. *N Engl J Med* **1996**; 335:76–83.
24. Medana IM, Day NP, Hien TT, et al. Axonal injury in cerebral malaria. *Am J Pathol* **2002**; 160:655–66.
25. Parums DV, Cordell JL, Micklem K, et al. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. *J Clin Pathol* **1990**; 43:752–7.
26. Erber WN, McLachlan J, Cordell JL, et al. A new monoclonal antibody (JC159) that detects glycophorin A for the diagnosis of erythroleukemia. *Hematol Rev* **1991**; 5:113–20.
27. Lu M, Zhang ZG, Chopp M. Analysis of cerebral microvascular architecture—application to cortical and subcortical vessels in rat brain. *J Neurosci Methods* **2004**; 138:81–7.
28. Lauwers F, Cassot F, Lauwers-Cances V, Puwanarajah P, Duvernoy H. Morphometry of the human cerebral cortex microcirculation: general characteristics and space-related profiles. *Neuroimage* **2008**; 39: 936–48.
29. Marchiafava E, Bignami A. “On summer-autumnal malaria fever.” In: *Malaria and the parasites of malaria fevers*. Vol 150. London: The New Sydenham Society, **1894**:1–234.
30. Newton CR, Hien TT, White N. Cerebral malaria. *J Neurol Neurosurg Psychiatry* **2000**; 69:433–41.
31. Milner DA Jr. Rethinking cerebral malaria pathology. *Curr Opin Infect Dis* **2010**; 23:456–63.
32. Clark IA, Cowden WB. The pathophysiology of falciparum malaria. *Pharmacol Ther* **2003**; 99:221–60.
33. Grau GE, Mackenzie CD, Carr RA, et al. Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria. *J Infect Dis* **2003**; 187:461–6.
34. Day NP, Phu NH, Mai NT, et al. The pathophysiologic and prognostic significance of acidosis in severe adult malaria. *Crit Care Med* **2000**; 28:1833–40.
35. Medana IM, Day NP, Sachanonta N, et al. Coma in fatal adult human malaria is not caused by cerebral oedema. *Malaria J* **2011**; 10:267.
36. Kawai S, Sugiyama M. Imaging analysis of the brain in a primate model of cerebral malaria. *Acta Trop* **2010**; 114:152–6.
37. Ellis CG, Jagger J, Sharpe M. The microcirculation as a functional system. *Crit Care* **2005**; 9(Suppl 4):S3–8.
38. Dondorp AM, Ince C, Charunwatthana P, et al. Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. *J Infect Dis* **2008**; 197:79–84.
39. Dondorp A, Nosten F, Stepniewska K, Day N, White N. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. *Lancet* **2005**; 366:717–25.
40. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. *Lancet* **2010**; 376:1647–57.